Invest in ME Conference 12: First Class in Every Way
OverTheHills wraps up our series of articles on this year's 12th Invest in ME International Conference (IIMEC12) in London with some reflections on her experience as a patient attending the conference for the first time.
Discuss the article on the Forums.

New Rituximab ME/CFS open-label phase II study with rituximab maintenance treatment

Discussion in 'Latest ME/CFS Research' started by Simon, Jul 1, 2015.

  1. Sasha

    Sasha Fine, thank you

    Messages:
    12,808
    Likes:
    34,302
    UK
    Another thing to add to the list for things we'd like Dr Nath to be aware of.
     
    Valentijn likes this.
  2. BurnA

    BurnA Senior Member

    Messages:
    2,086
    Likes:
    9,872
    If we get to 2018 and the phase 3 results are similar to the phase 2 results but no biomarker has been identified by then, what will happen from a research prerspective ?

    Will it be all hands on deck to unravel the puzzle of why RTX works or will things just tip along as before?
     
    L'engle likes this.
  3. Snow Leopard

    Snow Leopard Hibernating

    Messages:
    4,635
    Likes:
    12,500
    South Australia
    If the phase 3 results are similar then there will be a lot of attention! New people coming into the field to try and explain why it is working. Perhaps someone will win a Nobel prize!
     
    MEMum and L'engle like this.
  4. perrier

    perrier Senior Member

    Messages:
    693
    Likes:
    1,266
    Yes, but it's such a long time. First we have to get through 2016, then 2017, then 2018. In the meantime so much suffering, so much despair,so much life lost
     
    MEMum and PhoenixDown like this.
  5. Kati

    Kati Patient in training

    Messages:
    5,475
    Likes:
    19,639
    It's frustrating because good science takes time and bad science takes even longer to be erased.

    We are living every day 'in the meantime'. More research is needed, more funding, more physicians and more government representant needs to be educated. Let's get to work!
     
    Solstice, Jo Best, ryan31337 and 3 others like this.
  6. Jo Best

    Jo Best Senior Member

    Messages:
    1,031
    Likes:
    6,225
    I haven't read through all the recent comments so forgive me if this has been referred to already - that the paper on the initial B-cell study in the Invest in ME Research has now been published in hard copy (sorry, error, it was published in an early view of the journal not hard copy yet). I mention it here as this work is being done in close collaboration with the Norwegian team and is adding value to the Phase III trials. Collaboration on the rituximab-related studies also includes researchers in Spain, Sweden and Germany. It will be, hopefully, be further facilitated by the European ME Research Group, formed in 2015 by the European ME Alliance, and as usual, by the Invest in ME Conference & Colloquium events, where the Norwegian rituximab research is presented and discussed. This UK research is being crowdfunded and a blog was posted by Let's Do It for ME today - http://ldifme.org/first-paper-published-from-iime-funded-research/
     
    Last edited: Feb 27, 2016
    Justin30, Tuha, Kati and 7 others like this.
  7. Sasha

    Sasha Fine, thank you

    Messages:
    12,808
    Likes:
    34,302
    UK
    Hi Jo - do you mean it's been published in a journal?
     
  8. John Mac

    John Mac Senior Member

    Messages:
    321
    Likes:
    1,532
    Liverpool UK
  9. Bob

    Bob

    Messages:
    10,703
    Likes:
    34,252
    England (south coast)
    Yes, in the hard copy journal as opposed to online only.
     
    Sasha likes this.
  10. Scarecrow

    Scarecrow Revolting Peasant

    Messages:
    1,903
    Likes:
    5,386
    Scotland
    Bob, Sasha and BurnA like this.
  11. Jo Best

    Jo Best Senior Member

    Messages:
    1,031
    Likes:
    6,225
    Hi Sasha, apologies for the error, apparently, it was published in an early view of the journal not hard copy yet.
     
    Bob and Sasha like this.
  12. wastwater

    wastwater Senior Member

    Messages:
    1,049
    Likes:
    714
    uk
    Is there a pre,pre leukaemia.
     
  13. Murph

    Murph :)

    Messages:
    785
    Likes:
    3,813
    I've just been re-reading this paper and noticed they treated one person with ofatumumab and got a clinical response. searched this whole site, and @Snow Leopard 's mention of it above was the only one I found.

    These anti b-cell therapies are the best option we've got at the moment, and this morning I was only aware that Rituximab and Cyclophosphamide had been tried. Good to know there's at least one more lurking out there that the Norwegians are aware of!

    Seems ofatumumab can sometimes get into those hard-to-reach places Rituximab can't. https://www.ncbi.nlm.nih.gov/pubmed/25964296
    A possible alternative for non-responders?
     
    ScottTriGuy and helen1 like this.
  14. Snow Leopard

    Snow Leopard Hibernating

    Messages:
    4,635
    Likes:
    12,500
    South Australia
    I'm not sure how Ofatumumab can "get into those hard-to-reach places Rituximab can't."?
    The major difference is that this one is fully humanised, rather than chimeric and of course has many years of patent protection left. ;)

    Enhanced in vitro complement-dependent cytotoxicity activity is interesting, especially when your bosses want reasons to market a new drug's superiority over the old drug, but improved efficacy can only be demonstrated in clinical trials. Rituximab doesn't seem to have a problem in depleting B-Cells in most patients so...

    Also, perhaps it may also lead to higher risk of side effects...
     
    ScottTriGuy, L'engle and eljefe19 like this.
  15. Murph

    Murph :)

    Messages:
    785
    Likes:
    3,813
    I got the sense Ofa could kill some b-cells with low cd-20 levels? I interpreted the paper as saying it could get some mcl lines that showed "a high degree of in vitro resistance to rituximab associated with low CD20 levels and/or high expression of complement inhibitory proteins."

    Just trying to put this into terms my brain can remember easily! I've no idea how common low cd20 markers might be, nor how clinically relevant in me/cfs. I'm sure it has some upsides and some downsides and the fact Haukeland hospital is using Ritux preferentially suggests the balance is in that drug's favour.

    I very much take your point that it might well be being developed for profit reasons. And yet, might big pharma sensing some $ be just the trick for getting money put into a bit more cfs research?!
     
  16. Snow Leopard

    Snow Leopard Hibernating

    Messages:
    4,635
    Likes:
    12,500
    South Australia
    Yes, but that doesn't mean Ofa will be any better in vivo.

    There are claims that Ofa has tighter binding affinity, but clinical evidence is required as to whether this is actually useful in patients or not.

    I don't really know anything specific about the low CD20 phenotypes that you are talking about and whether they are important in the perpetuation of autoimmune illness (it's a good question for the likes of Edwards or Cambridge).
     
    Murph likes this.
  17. Jonathan Edwards

    Jonathan Edwards "Gibberish"

    Messages:
    5,255
    Likes:
    32,047
    The relevance of low CD20 levels only really applies to tumour clones derived from B cells that may have lost most of their CD20 expression - some high grade lymphomas. In autoimmune disease there is no reason why individual B cells should have low CD20 expression.

    If we are looking for the best anti-B cell antibody now available we are talking about new generation antibodies with fucose groups and such like. Ofatumumab has been around for at least a decade and we have no evidence it is better than rituximab in the clinic. Probably because it tends to engage complement more it tends to have more immediate adverse reactions from what I can see.
     
    Marky90, MeSci, deleder2k and 7 others like this.

See more popular forum discussions.

Share This Page